The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Tempus
Research Funding - Agenus (Inst); Boston Biomedical (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Placon (Inst); Stem Cells, Inc. (Inst); Tempus (Inst)
Travel, Accommodations, Expenses - Japanese Society of Clinical Oncology
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); Attica Sciences (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); Attica Sciences (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); Attica Sciences; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DYANIA HEALTH; Exelixis; Janssen; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Danny Khalil
No Relationships to Disclose
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); Gilead Sciences; Harbour BioMed; MedTree (I); Mundipharma; Seagen; ShangPharma Innovation; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bayer
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Checkpoint THerapeutics; Compass Therapeutics; Eisai; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
David Yoonsuk Oh
Consulting or Advisory Role - Maze Therapeutics
Research Funding - Merck (Inst); PACT Pharma (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent claiming methods for the use and optimization of cytotoxic CD4+ T cell therapy for cancer.; Inventor on patent claiming methods to identify patients who will respond to or experience toxicity with cancer immunotherapies based on T cell receptor sequencing.
Travel, Accommodations, Expenses - Roche/Genentech
 
Christopher R. Cabanski
No Relationships to Disclose
 
Michael Tezlaff
Honoraria - Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis
Consulting or Advisory Role - Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis
Travel, Accommodations, Expenses - Myriad Genetics; NanoString Technologies
 
Theresa LaVallee
Leadership - Lisen Imprinting Diagnostics
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Honoraria - Inovio Pharmaceuticals; NanoString Technologies
Consulting or Advisory Role - Exosis; Gerson Lehrman Group; Grey Wolf Therapeutics; Immatics; TRex Bio; Trishula Therapeutics
Patents, Royalties, Other Intellectual Property - Inventor on patents
 
Marko Spasic
Employment - IDEAYA Biosciences
Consulting or Advisory Role - Natera
 
Leo Nissola
No Relationships to Disclose
 
Lacey J. Kitch
No Relationships to Disclose
 
Nicholas L. Bayless
Employment - Centivax
Consulting or Advisory Role - Centivax
 
Cheryl Selinsky
Patents, Royalties, Other Intellectual Property - Issued patent "Method for Enhancing Immune Responses in Mammals" (Inst)
 
Jennifer C Ayran
Stock and Other Ownership Interests - Ultragenyx Pharmaceuticals (I)
 
Jill O'Donnell-Tormey
Leadership - HemaCare
Stock and Other Ownership Interests - HemaCare
 
Vanessa M. Hubbard-Lucey
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Ute Dugan
Employment - Bristol-Myers Squibb
Leadership - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
James Patrick Allison
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals (I); Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics (I); OPTERA; Phenomic AI; Phenomic AI (I); Polaris; Polaris (I)
Patents, Royalties, Other Intellectual Property - Inventor of a patent licensed to Merck; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; Polaris; Polaris (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); Codiak Biosciences; Codiak Biosciences (I); Constellation Pharmaceuticals; Dragonfly Therapeutics; Dragonfly Therapeutics (I); Forty Seven; Forty Seven (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; Jounce Therapeutics; Jounce Therapeutics (I); Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; Polaris; Polaris (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)